Abstract: A method of inhibiting anaphylaxis includes administering to a subject a composition comprising a first antibody, or fragment thereof, that binds to an allergen and a second antibody, or fragment thereof, that binds to the allergen, wherein the first antibody and the second antibody are from selected, epitope bins for an allergen that show the highest relative efficacy.

Abstract: In one aspect, methods of generating human monoclonal antibodies that specifically binds to an allergen are provided. In some embodiments, the monoclonal antibodies are generated from sequences identified from isolated single B cells from a human subject who is allergic to the allergen.

Abstract: The invention provides methods of testing food for antigens that are more stable to food processing than more clinically problematic allergens from the same food. When clinically-significant allergens are disproportionately broken down by common preparation methods, the presence of certain food ingredients may be “masked” to some tests yet may still be allergenic. To prevent false negative results due to food preparation, the invention provides tests that test for specific food antigens that are selected on the basis of their stability under processing. Antigens are selected for inclusion in the test not because they are the most clinically relevant allergens, but rather because they are robust to processing (e.g., and do not denature during cooking). Tests of the invention may also test for the most clinically relevant allergens, but importantly, by testing for stable protein products/antigens, the tests report the presence of food residues even after commercial processing.

Abstract: Systems and methods for recovering content of a sample from a microcapillary array are provided. The microcapillary array includes a plurality of microcapillary wells. A laser is positioned to target a first microcapillary well in the plurality of microcap-wells. The laser pulses at least one time at the first microcapillary well. The content from the first microcapillary well is extracted, recovering the content of the first microcapillary well.

Abstract: The present invention provides systems and methods for predicting an allergic response in a subject by measuring the amounts of RNA species from B cells that encode at least a part of the Immunoglobulin E (IgE) constant region (C?), such as nonproductive epsilon germline transcripts (?GLTs).

Abstract: In one aspect, methods of generating human monoclonal antibodies that specifically binds to an allergen are provided. In some embodiments, the monoclonal antibodies are generated from sequences identified from isolated single B cells from a human subject who is allergic to the allergen.

Abstract: The invention generally relates to therapeutic compositions and methods for treating and suppressing allergic responses.

Abstract: In one aspect, methods of generating human monoclonal antibodies that specifically binds to an allergen are provided. In some embodiments, the monoclonal antibodies are generated from sequences identified from isolated single B cells from a human subject who is allergic to the allergen.

Abstract: In one aspect, methods of generating human monoclonal antibodies that specifically binds to an allergen are provided. In some embodiments, the monoclonal antibodies are generated from sequences identified from isolated single B cells from a human subject who is allergic to the allergen.

Abstract: In one aspect, methods of generating human monoclonal antibodies that specifically binds to an allergen are provided. In some embodiments, the monoclonal antibodies are generated from sequences identified from isolated single B cells from a human subject who is allergic to the allergen.

Abstract: Provided are antibodies or antigen binding portions thereof that specifically bind Dengue virus, various compositions of such antibodies or antigen binding portions thereof, and methods of their use. The disclosure provides such antibodies, fragments of such antibodies retaining Dengue virus-binding ability, pharmaceutical compositions including such antibodies or antigen binding fragments thereof, and diagnostic compositions including such antibodies or antigen binding fragments thereof. This disclosure further provides for isolated nucleic acids encoding such antibodies, amino acid sequences of such antibodies, and host cells transformed therewith. Additionally, this disclosure provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the disclosure.